Capital Budgeting, Project Selection, and Performance Evaluation - Chapter 5 Retelling
Book: Structured Finance and Insurance: The ART of Managing Capital and Risk Author: Christopher L. Culp Publisher: Wiley Finance, 2006 ISBN: 978-0-471-70631-1
Chapter 5 is the longest in Part One, and for good reason. It’s about how companies actually decide where to put their money. Capital budgeting sits at the intersection of everything we’ve covered so far: real capital, financial capital, risk, leverage, and adverse selection.
The question is straightforward: which projects should the firm invest in? But the answer turns out to be surprisingly hard to get right. Culp walks through the popular methods firms use, explains what’s wrong with most of them, and then builds up to the approach that actually works.
The Accounting Metrics (And Why They Fail)
A lot of companies still make investment decisions based on accounting numbers. Culp covers the main ones and doesn’t hold back on their flaws.
Earnings and EPS growth. Many firms treat steady earnings growth as the holy grail. High P/E ratios are seen as a sign of strength. But earnings are a terrible basis for investment decisions. They’re sensitive to accounting rules that can change. They don’t reflect the true cash flow impact of investments. They ignore risk entirely. And they don’t account for the time value of money.
Culp brings up Enron as the extreme example. Enron was obsessed with maintaining earnings growth and a high P/E target. They managed to do it while simultaneously hemorrhaging cash. That worked until it didn’t.
Return on Investment (ROI). This was supposed to fix earnings by creating a ratio. It doesn’t. ROI understates the value of projects early and overstates it late because of declining depreciated asset bases. It’s hypersensitive to the initial investment amount. It ignores off-balance-sheet items. And it makes no attempt to control for risk.
Return on Equity (ROE). Has all the same problems as ROI plus an unhealthy sensitivity to leverage. If a project earns more than the cost of debt, you can artificially boost ROE by financing it with more debt. The calculation doesn’t penalize you for pushing the firm away from its optimal capital structure in the process.
Cash Flow Methods Without Risk Adjustment
Moving to cash flow methods is better, but we’re still not there.
Market ROI uses actual cash flows and market values instead of accounting numbers. A big improvement. But it still doesn’t control for risk, which means it can lead to bad decisions when comparing projects of different riskiness.
Internal Rate of Return (IRR) is the rate that makes a project’s NPV equal zero. It’s intuitive (it’s the break-even return) and uses cash flows. But IRR breaks down when comparing mutually exclusive projects or when capital must be rationed. It works fine for evaluating a single project in isolation, but that’s not how most firms operate.
The NPV Rule
The Net Present Value rule is the gold standard, and Culp makes a strong case for it.
The NPV of a project is the present value of all expected future net cash flows minus the initial investment, where the cash flows are discounted at an appropriate risk-adjusted rate. Accept all projects with NPV greater than or equal to zero. Reject the rest.
This sounds simple, but the two inputs, expected cash flows and discount rates, are both hard to estimate in practice.
Cash flow estimation is “two parts art, one part science.” You need to use actual cash flows, not accounting numbers. Be careful with economies of scope (don’t allocate shared overhead to a project unless the project genuinely increases cash outflows). Never include sunk costs. Do include opportunity costs, externalities on other parts of the firm, and working capital contributions.
Discount rates are where things get really tricky. Culp walks through several issues:
The CAPM is still the most common way to estimate a discount rate, despite its well-known problems. Fama and French have shown that other factors (firm size, book-to-market ratio) provide additional explanatory power. But there’s no consensus on which factors to use, and the parameter estimates are often too imprecise to be useful. The CAPM survives not because it’s the best model, but because it’s the simplest and most internally consistent. As Fama and French themselves note, “two of the ubiquitous tools in capital budgeting are a wing and a prayer.”
Should you use the project’s specific risk or the firm’s WACC? Ideally, you’d use the project’s own expected return on assets. But data is usually too scarce. Most firms use their WACC instead. This works as long as the project’s risk is roughly similar to the firm’s average risk. If the project is much riskier than the firm, WACC will be too low and you’ll overinvest. If it’s safer, WACC will be too high and you’ll underinvest.
In a non-M&M world, idiosyncratic risks matter too. If shareholders can’t diversify away certain firm-specific risks (because information is asymmetric or markets are imperfect), they’ll demand a higher expected return. The WACC needs to be adjusted upward to reflect this.
Real Options and Strategic NPV
This is the section where Chapter 5 really shines. Culp builds on the growth opportunities concept from Chapter 1 and shows how real options should be incorporated into capital budgeting.
The basic NPV rule looks at projects in isolation. But many projects come with built-in strategic options that have real value. Ignoring them leaves money on the table.
The option to wait. Even a project with a positive NPV today might be worth more if you wait. Ingersoll and Ross (1992) show that interest rate uncertainty alone can make waiting valuable. If there’s any chance rates will fall, a project that looks marginal today could look great tomorrow. This has value right now, even though you haven’t committed to anything.
The deferral option. When project cash flows themselves are uncertain (not just interest rates), the option to delay becomes even more valuable. Higher uncertainty means higher option value. More time to decide means higher option value. Sound familiar? These are the same variables that drive financial option prices.
The abandonment option. The ability to shut down and sell assets if things go badly. This is a put option. If the liquidation value exceeds the value of continuing operations, you exercise. Common in capital-intensive industries like transportation and financial services.
The time-to-build option. Stage your investment in phases with the ability to walk away at each stage if new information makes the project look bad. Every stage is a compound option. This is how pharmaceutical R&D works: invest in stages, abandon if the drug isn’t working. Culp references Danny DeVito’s famous speech in “Other People’s Money” about buggy whips. If you’re mid-investment in a buggy whip factory when the automobile arrives, the option to abandon has real value.
The option to alter operating scale. Expand if demand is higher than expected. Contract (or temporarily shut down) if demand drops. Common in natural resources, construction, and fashion-sensitive industries.
The switching option. Change your inputs or outputs. Electric utilities that can switch between gas, coal, and nuclear. Airbus lets airlines buy options on aircraft families rather than specific models, giving them the flexibility to choose based on actual demand at the time of exercise.
Interactive growth options. Where investing in one project opens up opportunities for others. Mergers and acquisitions often have this feature. You’re buying the target’s real options along with its current assets.
The strategic NPV is just the regular NPV plus the value of all these real options. In many situations, the real options are worth more than the underlying project itself.
SVA, EVA, and CFROI
Culp covers three more sophisticated frameworks that build on NPV.
Shareholder Value Added (SVA) values the whole firm before and after a project, focusing on marginal contribution to shareholder wealth. It uses a forecast period with explicit per-period cash flows plus a residual value for everything beyond.
Economic Value Added (EVA) is net operating profit after taxes minus a capital charge for the investment required. When you discount EVA at the WACC, you get NPV. EVA is often criticized as a short-term snapshot, but it’s really an annualized equivalent of NPV. Its main weakness is reliance on book value.
Cash Flow Return on Investment (CFROI) is basically a post-tax IRR for existing assets. In theory, it leads to the same decisions as EVA.
Culp notes that SVA is probably the most realistic of the three because it uses forward-looking asset values rather than sunk cost measures of past investment spending.
My Take
Chapter 5 is essential background for understanding why risk management matters in a capital budgeting context. The connection might not be obvious at first, but it becomes clear when you think about it.
Risk capital, the financial capital set aside to absorb specific losses, is a direct input into the capital budgeting process. If a firm has to hold extra equity because of risk exposure, that’s capital that could have been deployed elsewhere. Risk transfer can reduce the required equity buffer. Risk finance can help ensure cash is available when needed for investment. Both affect which projects get funded and which don’t.
The real options discussion is also directly relevant. Many structured finance and ART products effectively create or protect real options. A contingent capital facility (coming in later chapters) protects a firm’s ability to invest after a loss. That’s essentially preserving the firm’s growth opportunities, the real options that could be lost if cash runs short at the wrong time.
One line from Fama and French stuck with me: even with the best models, capital budgeting relies on “a wing and a prayer.” That’s honest in a way that most finance textbooks aren’t. Models give us a framework for thinking. They don’t give us precision.